BMEA
HealthcareBiomea Fusion, Inc.
$1.28
$-0.06 (-4.48%)
Jan 5, 2026
Price History (1Y)
Analysis
Biomea Fusion, Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $90.50 million and 42 employees, it falls into the category of smaller-scale entities in its industry. The company's financial health is characterized by significant losses, with net income totaling -$95,711,000 over the trailing twelve months. Additionally, Biomea Fusion has negative EBITDA of -$97,831,000 and free cash flow of -$55,621,752 during this period. The firm holds $46.64 million in cash against a debt of $6.88 million, which translates to a current ratio of 3.18. However, its profitability is marked by negligible gross margin, operating margin, and profit margin of 0.0% each. Biomea Fusion's valuation context features a negative forward P/E ratio of -1.25 and an EV/EBITDA of -0.56. The company's price to book ratio stands at 4.89.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Visit website →Key Statistics
- Market Cap
- $90.50M
- P/E Ratio
- N/A
- 52-Week High
- $4.59
- 52-Week Low
- $0.87
- Avg Volume
- 1.94M
- Beta
- -0.17
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 42